Ocular drug delivery has constantly challenged ophthalmologists and drug delivery
scientists due to various anatomical and physiological barriers. Static and dynamic ocular …

Nanocarriers have therapeutic potential to facilitate drug delivery, including biological
agents, small-molecule drugs, and nucleic acids. However, their efficiency is limited by …

Vision impairment and loss due to posterior segment ocular disorders, including age-related
macular degeneration and diabetic retinopathy, are a rapidly growing cause of disability …

Calcium phosphate nanoparticles represent promising materials for drug delivery because
of its favorable properties, including biocompatibility, biodegradability and strong affinity for …

Ocular diseases profoundly impact patients' vision and overall quality of life globally.
However, effective ocular drug delivery presents formidable challenges within clinical …

A drawback in the development of treatments that can reach the retina is the presence of
barriers in the eye that restrain compounds from reaching the target. Intravitreal injections …

Pathological ocular neovascularization resulting from retinal ischemia constitutes a major
cause of vision loss. Current anti‐VEGF therapies rely on burdensome intravitreal injections …

Background Glaucoma is the first irreversible and second blindness disease, which is
characterized by the death of retinal ganglion cells (RGCs) and degeneration of the optic …

Nanomedicine is an innovative field that merges nanotechnology with medicine, aiming to
enhance diagnosis, treatment, and prevention of diseases at the molecular level. This …

Nutraceuticals are natural substances whose anti-oxidant and anti-inflammatory properties
may be used to treat retinal pathologies. Their efficacy is limited by poor bioavailability …